TITLE

Psychological Effect, Pathophysiology, and Management of Androgenetic Alopecia in Men

AUTHOR(S)
Stough, Dow; Stenn, Kurt; Haber, Robert; Parsley, William M.; Vogel, James E .; Whiting, David A.; Washenik, Ken
PUB. DATE
October 2005
SOURCE
Mayo Clinic Proceedings;Oct2005, Vol. 80 Issue 10, p1316
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Androgenetic alopecia in men, or male pattern baldness, is recognized increasingly as a physically and psychologically harmful medical condition that can be managed effectively by generalist clinicians. This article discusses the clinical manifestations, epidemiology, physical and psychosocial importance, pathophysiology, diagnosis, and management of androgenetic alopecia in men. Androgenetic alopecia affects at least half of white men by the age of 50 years. Although androgenetic alopecia does not appear to cause direct physical harm, hair loss can result in physical harm because hair protects against sunburn, cold, mechanical injury, and ultraviolet light. Hair loss also can psychologically affect the balding individual and can influence others' perceptions of him. A progressive condition, male pattern baldness is known to depend on the presence of the androgen dihydrotestosterone and on a genetic predisposition for this condition, but its pathophysiology has not been elucidated fully. Pharmacotherapy, hair transplantation, and cosmetic aids have been used to manage male pattern baldness. Two US Food and Drug Administration-approved hair-loss pharmacotherapies—the potassium channel opener minoxidil and the dihydrotestosterone synthesis inhibitor finasteride are safe and effective for controlling male pattern baldness with long-term daily use. Regardless of which treatment modality is chosen for male pattern baldness, defining and addressing the patient's expectations regarding therapy are paramount in determining outcome.
ACCESSION #
18541525

 

Related Articles

  • Alopecia areata: new hope for the hopeless. Gillette, Bill // Dermatology Times;Aug2015, Vol. 36 Issue 8, p1 

    The article focuses on the effectiveness of tofacitinab as a treatment for alopecia, which was discussed by physicians Neal Bhatia and Ted Rosen during their presentation "New Drugs and New Concepts" at the MauiDerm 2015. It discusses a case report involving a plaque psoriasis patient being...

  • New help for female hair loss. Rock, Maxine // Prevention;Jul90, Vol. 42 Issue 7, p58 

    Discusses latest medical helps for female hair loss. Analyzing the problem; Common hair loss; Drug options; Surgery; New experiments.

  • Information from Your Family Doctor: Hair Loss in Women.  // American Family Physician;3/1/2003, Vol. 67 Issue 5, 'Special section' p1017 

    Focuses on hair loss in women. Types of hair loss; Information on alopecia areata; Treatment for hair loss.

  • The Efficacy of Intermittant Low-Dose Systemic Corticosteroid in the Treatment of Alopecia Areata. Birol, Ahu; Erkek, Emel; Tuncez, Fatma; Saylam Kurtipek, Gülcan; Bağci, Yeter; Koçak, Mukadder // Turkish Journal of Medical Sciences;2004, Vol. 34 Issue 1, p55 

    Alopecia areata (AA) is a common cause of non-scarring alopecia characterized by patchy hair loss. AA is difficult to treat because of its chronic and inflammatory nature. The aim of the present study was to investigate the effect of low-dose systemic corticosteroids in the treatment of...

  • Quantifiable guidelines. Guttman, Cheryl // Dermatology Times;May2004, Vol. 25 Issue 5, p96 

    Discusses the current status of evidence-based therapy for alopecia areata. Evaluation of topical steroids in randomized, double-blind, placebo-controlled studies; Opinion on the quality of evidence and recommendation for minoxidil and topical anthralin; Treatment for patients with severe...

  • Lost Opportunity. Cook, John // Instyle;Nov/Dec2010, Vol. 16 Issue 16, p149 

    The article focuses on the follicle stimulation programme (FSP) that helps counteract fibrosis or the hardening of the collagen structure of hair follicles which can diminish hair growth. It discusses the causes of senescent alopecia or hair loss and suggests several products to treat the...

  • Alopecia accuracy. Jesitus, John // Dermatology Times;Aug2012, Vol. 33 Issue 8, p51 

    The article discusses management and treatment of female pattern alopecia (FPA). The condition of FPA is characterized by hair loss that is diffuse thinning of hair over the top of the scalp. A systematic approach helps to guide the workup and management of FPA. Androgens are known to play a...

  • Leczenie ogólne Å‚ysienia plackowatego. Łuczak, Magdalena; Łuczak, Tomasz; Cieścińska, Czanita; Czajkowski, Rafał // Dermatology Review / Przeglad Dermatologiczny;2013, Vol. 100 Issue 1, p53 

    Alopecia areata is a recurrent, non scarring type of hair loss. Etiologic factors have not been fully explored. The incidence of the disease is estimated to be 1-2% of the general population. Therapeutic management can be divided into local and general treatment, phototherapy and psychological...

  • Saç dökülme tedavisinde mezoterapi ve trombositten zengin plazma. Gökdemir, Gonca // Archives of the Turkish Dermatology & Venerology / Turkderm;2014 Supplement1, Vol. 48, p74 

    Hair loss often significant impact on quality of life, including loss of self-confidence and self-esteem. However, treatment of hair loss is frustrating for both patients and doctors. Mesotherapy and platelet-rich plasma have recently become advertised method for the treatment of different types...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics